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Abstract 
The nitric oxide pathway plays a pivotal, yet diverse, role in human physiology, 
including modulation of vascular tone, neural transmission and inflammation. 
Inhaled nitric oxide is a selective pulmonary vasodilator that has emerged rapidly 
as an important therapeutic agent. It finds its best applications in paediatrics; the 
use of iNO in term neonates with hypoxaemic respiratory failure, in the 
assessment of pulmonary vascular reactivity and in the treatment of 
postoperative pulmonary hypertension in congenital heart disease is well 
recognised and accepted. This review details the delivery and monitoring aspects 
of inhaled nitric oxide, its potential toxic and side effects and its applications in 
several cardiopulmonary disorders in paediatrics. 
MeSH: Heart defects, congenital, Hypertension, pulmonary, Infant, premature, 
Newborn, Nitric oxide, Paediatrics 
 
Introduction 
Inhaled nitric oxide (iNO) therapy is nowadays recognised as an important tool for 
the treatment and diagnosis of pulmonary vascular and airspace disease. Nitric 
oxide (NO) is a naturally occurring gas with multiple biological actions. 
Endogenous NO plays a role in the modulation of vascular tone,1,2 the regulation 
of platelet function, neuronal transmission and the inflammatory response.3 NO is 
formed, in the endothelial cell, from L-arginine and molecular oxygen in a reaction 
catalysed by the enzyme nitric oxide synthase (NOS).4 Three different isoforms of 
NOS exist: NOS 1, a constitutive form first identified in neurons named nNOS; 
NOS2, an inducible form, first found in activated leukocytes called iNOS; and 
NOS 3, identified in endothelial cell also called eNOS. Even if very similar in 
structure, they show some differences. NOS 1 and 3 are constitutively expressed 
and are calcium calmodulin dependent. NOS 2, in contrast, is seen after 
induction by inflammatory stimuli, and is calcium independent. Nitric oxide 
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synthase 2 can produce large amount of NO measured in nanomoles, instead of 
the picomoles produced by the nitric oxide synthase 1 and 3. NO thus formed is a 
small reactive molecule which diffuses readily to adjacent vascular smooth 
muscle. In the vascular smooth muscle NO activates guanylate cyclase, which 
transforms GTP into cyclic guanylate monophophate (cGMP), which in turn 
induces vasodilatation.5 As NO exists as a gas, it can be delivered by inhalation, 
hence NO can vasodilate constricted blood vessels in close proximity to the 
ventilated lung. The rapid inactivation of NO by haemoglobin, when NO reaches 
the intravascular space, limits its effects on the pulmonary circulation.6 
In this review, we will first describe the delivery and monitoring of inhaled NO 
(iNO) as well as its potential adverse effects and toxicity. These aspects are 
essential to the safe use of iNO. We shall then discuss its different applications in 
paediatric practice. 
 Rationale for the use of inhaled nitric oxide 
For many years, physicians involved with the care of patients with pulmonary 
hypertension were in search of the ideal pulmonary vasodilator, which should be 
easy to administer, have a short duration of action and above all, be selective for 
the pulmonary circulation. Approaches to manipulate the pulmonary vascular 
tone were limited to oxygen supplementation7,8 and respiratory or metabolic 
alkalosis.9,10 Drug therapy included several intravenous vasodilators such as 
prostaglandins,11,12 tolazoline13 and magnesium sulphate.14,15 All were 
characterised by their lack of selectivity, leading to a fall in systemic arterial 
pressure and an increase in intrapulmonary shunt. The introduction of inhaled NO 
and other recent advances in vascular biology have drastically changed the 
therapeutic approach of pulmonary hypertension. 
As nitric oxide exists as a gas, it can be easily administered by inhalation. The 
anatomical proximity of the airspaces to the muscular arterioles allows NO to 
diffuse. Nitric oxide is lipophilic and thus crosses the membranes easily. By 
inducing vasodilation of aerated airspaces, NO can redirect blood flow from 
poorly ventilated areas, atelectatic or diseased lung regions, to better aerated air 
spaces and improves oxygenation and ventilation perfusion mismatch. This effect 
is the so-called microselective effect of iNO. As for endogenous NO, this 
vasodilator effect is induced through the cyclic cGMP pathway, as demonstrated 
by an increase in plasma cGMP during iNO therapy.16,17 When it reaches the 
vascular lumen, NO avidly binds to haemoglobin and is thereby inactivated with a 
half-life of 2-6 seconds.18 This rapid inactivation limits its effects on the pulmonary 
circulation and accounts for its selective action.6,19 This is the macroselective 
effect of iNO. Indeed, red blood cells act as scavengers of iNO as demonstrated 
by Deem et al.20 Between 75 and 90% of iNO is absorbed during inhalation. The 
metabolic fate of iNO is indeed similar to endogenous NO with the formation of 
nitrites and nitrates eliminated in the urine,21 and more than 70% of the inhaled 
gas will appear in the urine as nitrates within 48 hours of inhalation.22,23 
In summary, iNO fulfils most of the properties required to be the ideal pulmonary 
vasodilator; thus its use has become of major clinical interest. 
 Delivery and monitoring 
The potential toxicity of iNO calls for reliable modes of delivery and availability of 
monitoring systems. Large and extensive reviews of the diverse modes of iNO 
delivery have been published.24–32 The exact method of delivery and monitoring 
of NO may vary with the clinical indication and duration of treatment as well as 
the type of ventilator used. NO source tanks should be medical grade quality gas 
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manufactured by a process accepted by the medical administration and is 
available in different concentrations of NO in N2, from 100 to 10000 ppm. By 
using continuous flow ventilators, stable NO concentrations can be easily 
delivered by titrating NO directly from the tank into the inspiratory limb of the 
ventilator. The theoretical concentration can be calculated using the following 
formula: NOconc= NOtankx(FlowNOtank/Flowventilator). However, as demonstrated by 
Betit et al.32 NO concentrations can be underestimated and direct measurement 
of NO is mandatory during therapy. 
NO can also be administered with demand valve systems using a similar 
technique but a stable concentration of NO may be difficult to obtain. It has been 
proposed to deliver NO with a synchronised inspiratory injection technique to 
avoid the inconvenience of delivery during expiration.33 Ventilators equipped with 
in-built NO delivery and monitoring systems are currently available. They simplify 
delivery and improve safety. The recent development of new ventilatory 
techniques such as high frequency oscillation ventilation (HFO) in newborns or 
infants with respiratory failure open new challenges for iNO deliveries, but 
because HFO is also delivered at constant flow, it seems possible to obtain 
stable NO concentrations.34,35 Fujino et al reported that mixing NO during HFO 
was acceptable at all injection sites with a preference for the prehumidifier 
injection, which offers less fluctuation of NO concentration.36 However, with this 
latter ventilatory technique, measurements may not be accurate, as a prolonged 
residency time of NO in the airways is possible; also the concentrations 
measured at the inspiratory limb of the ventilator do not accurately reflect the 
effective NO concentrations in the alveoli. 
In spontaneously breathing patients NO can be administered by mask or hand 
ventilation with a bag.37–39 Administration through nasal prong is also possible, 
opening the possibility of long-term treatment with iNO.40 
The appropriate dose of iNO to assess pulmonary vascular resistance or treat 
pulmonary hypertension is not completely defined. Dose response studies have 
been performed in persistent pulmonary hypertension of the newborn (PPHN) 
and ARDS41–46 and in congenital heart disease.47,48 Inhaled NO doses required to 
treat pulmonary hypertension are higher than those required for improvement of 
ventilation perfusion mismatch and oxygenation.41 The recommended dose by 
the FDA for the treatment of neonatal hypoxic respiratory failure is 20 ppm. 
Recently, Tworetzky et al suggest an initial dose of 20 ppm for the treatment of 
PPHN, as it produced an improvement in the pulmonary to systemic arterial 
pressure ratio, even though 5 ppm iNO was enough to produce peak 
improvement in oxygenation.49 The exact dose required may indeed vary not only 
with the pathology but also with duration of therapy. Nelin et al. showed that the 
effective dose (the smallest dose effective to obtain a beneficial response) 
decreases as therapy continues.50 
It has been shown that there is little haemodynamic benefit obtained above 20 
ppm. The dose used to assess pulmonary vascular reactivity varies between 10 
and 40 ppm, rarely 80 ppm, but higher doses had no further effect. The same 
may be applied for postoperative cardiac patients with a starting dose between 
10 and 20 ppm. If there is no response, a trial at 40 and 80 ppm may be 
attempted but questions about the diagnosis must be raised. Higher doses give 
little or no benefit but may be associated with an increased risk of toxicity, in 
particular NO2 and methaemoglobin formation. When a response is obtained, the 
dose must be decreased progressively to the lowest effective dose to avoid 
potential toxic effects. Slightly higher doses may be required for PPHN but Finer 
et al. showed that maximal response was obtained with 5 ppm.44 Adequate 
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ventilation and lung recruitment is necessary in these patients to deliver NO in 
the alveoli and obtain a result. ARDS patients sometimes respond to very low 
doses of some hundreds ppb. 
Guidelines on the use of NO with an emphasis on safety have emerged from a 
NHLBI workshop.51 An ideal delivery system uses medical grade NO, limits to the 
maximum the residency time of NO in the ventilatory circuit, allows for precise 
concentrations of NO with a uniform mixing, has alarms notifying when excessive 
concentrations of NO are administered or if inadvertent discontinuation of NO 
occurs. Most important of all, it allows on line monitoring of NO and NO2. 
The formation of NO2 is in part correlated to the amount of NO administered and 
a correct measurement of NO concentrations is of utmost importance. Two 
systems are currently available for monitoring NO and NO2 concentrations. 
Chemiluminescence technique remains the gold standard with an accuracy of 
some ppb.52 Manufacturers have adapted industry materials to the requirement of 
medicine with rapid response analysers requiring small amount of air sampling 
and therefore not interfering with ventilation. However, these devices are 
expensive and one may prefer the electrochemical devices that are somewhat 
inaccurate to measure very low amount of NO (such as for measurement of 
exhaled NO) but accurate enough by far for treatment monitoring.53 
 Toxicity 
There has been proper concern about the potential toxicity of NO therapy. NO is 
a common pollutant. The US Occupational Safety and Health Administration has 
set a limit of NO exposure time to 25 ppm when breathed for 8h/day in the 
workplace.54 
No severe side effects of iNO have been described, using concentrations up to 
40 to 80 ppm (the maximal doses used in clinical practice). Studies in rats have 
shown that inhalation of NO up to 1500 ppm for 15 min caused no demonstrable 
injury.55 Moreover cigarette smoke contains NO concentrations up to 1000 ppm56 
and no acute toxic effects have been reported. However, NO may be one of the 
substances involved in long-term lung toxicity of cigarette smoke. If extreme 
doses are used it seems to lead rapidly to methaemoglobinemia and a toxic 
pulmonary oedema, which may be more related to the transformation of NO to 
NO2than to a direct effect of NO.57 Therefore, particular attention has been 
focused on the possible acute toxic effects such as the production of NO2 (a 
pulmonary toxin), methaemoglobinemia (which should remain < 5%), and cellular 
toxicity. 
 NO2 
One of the main concerns of iNO therapy is the chemical reaction of NO to NO2 in 
the presence of oxygen within the ventilatory system or the airways. NO2 is 
thought to be responsible for the pulmonary injury caused by exposure to NO. 
NO2 is clearly cytotoxic55 and in aqueous solutions is transformed to nitric and 
nitrous acids. It causes pulmonary epithelial cell damage, interstitial atrophy and 
fibrosis.55 It is generally accepted that concentrations of NO2 over 5 ppm are 
toxic.54,58 Production of NO2 is function of the NO concentration squared, the 
fraction of inspired oxygen and the time of residency in the ventilatory system. 
Based on these findings guidelines should be followed to minimise the risk of 
toxicity related to the formation of NO2: 
1. Administer the lowest effective dose of iNO with a maximal dose of 40 
to 80 ppm 
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2. Administer the lowest possible concentration of O2 
3. Monitor O2 , NO and NO2 concentrations 
4. Minimise the transit time in the ventilator by using high gas flow rates to 
flush out alveolar gases 
5. Minimise the exposure time of NO to oxygen before it reaches the 
patient 
 Methaemoglobin 
Inhaled NO is quickly absorbed into the blood stream, avidly bound to 
haemoglobin and thereby, inactivated with the formation of methaemoglobin. This 
oxidised form of haemoglobin has impaired oxygen transport function. 
Methaemoglobin is restored to its oxygen carrying capacity by methaemoglobin 
reductase. Increased levels of methaemoglobin in patients receiving iNO therapy 
are unusual, and remain for the great majority in a safe range (<5%). High levels 
of methaemoglobin have rarely been reported.59,60 Neonates have an immature 
methaemoglobin reductase system and may be more susceptible to increased 
levels.61 Of note, methaemoglobin reductase deficiency is common in Native 
Americans.62 
Methaemoglobin will indeed remain in a safe range with doses of iNO of 40 ppm 
and less. If necessary, excess methaemoglobin may be treated by reducing the 
iNO concentrations, or administrating vitamin C or methylene blue.24,63–65 
Particular caution must be taken when intravenous nitrovasodilators are 
associated with iNO, i.e. in the postoperative cardiac patient, where in our 
experience higher levels of methaemoglobinemia might be encountered. 
 Cellular effects 
NO reacts with O2 and superoxide anion (O2-) to form peroxinitrite. Peroxinitrite is 
a potent oxidant that may damage a wide range of biological molecules.66 In 
particular, it can induce lipid peroxidation of the cell membrane. Peroxinitrite also 
cause cell apoptosis by DNA strand breakage and by inhibition of mitochondrial 
respiratory enzymes.67 However, NO is also considered as a free radical 
scavenger which can counteract and stabilise peroxinitrite. The significance of 
peroxinitrite-induced toxicity during inhaled NO therapy remains unknown. The 
antioxidant versus oxidant balance of these reactions may depend of the relative 
concentrations of these molecules and potential toxicity may only appear with 
high doses of NO not routinely used in clinical practice. 
NO can react with thiol groups and form S-nitrosothiols.68 These forms may act 
as NO carriers and transport NO far from its delivery site in the lung. Indeed S-
nitrosothiols have similar platelet and vasorelaxant activities as NO and may 
prolong its effects or displace its site of action.69 
One of the other major potential toxic effects at the cellular level is the effect on 
DNA. NO can inhibit DNA synthesis70 and it has been shown that NO can alter 
DNA by the direct modification and strand breakage of DNA and also by inhibition 
of enzymes that are necessary to repair DNA lesions.71,72 
 Long term follow-up 
Long-term studies of iNO in paediatrics are still scarce. In 12 newborns who 
received iNO for up to 4 days, no signs of lipid peroxidation product, impaired 
surfactant activity or changed cytokine profile were observed.73,74 On the other 
hand, nitrotyrosine was detected after 10 days of life in two infants requiring 
prolonged ventilation, suggesting potential toxicity of NO.73 Follow-up studies of 
adult patients treated with iNO for ARDS showed no difference in pulmonary 
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function compared to ARDS patients not treated with iNO.75 Dobyns et al. came 
to the same conclusions in infants treated with iNO for PPHN and studied 4 to 12 
months after discharge from the hospital.76 In hypoxaemic term neonates, iNO is 
not associated with an increase in neurodevelopmental, behavioral or medical 
abnormalities at 2 years of age.77 A recent follow up review of patients with PPHN 
randomised to a treatment with iNO demonstrated no adverse health or 
neurodevelopmental outcomes have been observed among infants treated with 
NO vs controls.78 
In summary, so far no long-term toxic effects have been reported but caution 
must be the rule with this molecule with its wide variety of biological activities and 
potential toxicity. 
 Adverse effects 
Some of the unwanted effect of nitric oxide may not be categorised as toxic 
effects but as adverse effects. 
 Rebound pulmonary hypertension 
When iNO is administered over a prolonged period, such early as after cardiac 
surgery or in newborns with hypoxaemic respiratory failure, a considerable rise in 
pulmonary artery pressure may appear at time of abrupt withdrawal of iNO.79–83 
This may be a self resolving problem in a few minutes but can also progress to 
right ventricular failure and low cardiac output which may be life threatening. 
Different mechanisms can explain this reaction, ie: a possible down regulation of 
the endogenous production of NO by the administration of exogenous iNO, a 
slow recovery from cell dysfunction taking several days or a combination of both. 
Recently, an increase in endogenous endothelin has also been suggested as a 
potential mechanism.84 
A negative feedback mechanism is supported by several studies both in vitro and 
in vivo85–89 and is probably the main effect responsible of this phenomenon. 
Exhaled NO is reduced after cardiopulmonary bypass due to either a decreased 
production or increased breakdown.90 Endothelial cell dysfunction after 
cardiopulmonary bypass, as demonstrated by Wessel et al., may therefore take 
some days to recover and resume production of endogenous NO.16 Withdrawal of 
iNO during this period leads to rebound pulmonary hypertension. This was also 
supported by Combes et al. showing that NO inhalation for 48 hours increases 
the reactivity of the pulmonary vascular bed to vasoconstricting agents.89 
In order to avoid this rebound phenomenon, a stepwise slow reduction of iNO is 
mandatory and this even at very low levels of iNO such as 1 ppm. Regular 
attempts to wean should be performed to avoid self-maintaining treatment with 
iNO leading to a prolonged postoperative course.91 Several other methods have 
been proposed: a transient increase in the fraction of inspired oxygen by Aly et 
al.,92 the use of dipyridamole, a phosphodiesterase inhibitor allowing to maintain 
high levels of cGMP in the smooth muscle cell, thus prolonging the effect of 
iNO.93,94 The use of sildenafil has also been reported recently.95 
 Platelet function 
Endogenous NO has multiple biological functions among which the regulation of 
platelet function.96 Hoggman et al. first reported that iNO inhibits platelet function 
and prolongs bleeding time in rabbits.97 In patients with ARDS, NO decreased 
platelet aggregation but had no effect on bleeding time.98 Intracranial 
haemorrhage is one of the most serious concerns in neonates, particularly in 
preterm neonates. Therefore the application of iNO in this group of patients 
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raises some concerns. Studies in neonates are conflicting: George et al.99 
showed that the bleeding time was increased after 30 min of 40 ppm iNO, 
whereas several other clinical studies demonstrated no change in the frequency 
of bleeding events in NO treated compared to placebo treated neonates.35,59,100 
Furthermore, recent studies in near terms and premature neonates did not 
demonstrate an increased risk of intracranial haemorrhage.100,101 
We have shown that, in healthy volunteers, 10 min iNO at 30 ppm induced an 
inhibition of platelet aggregation accompanied by an increase in plasma and 
platelet cGMP.102 This effect is of short duration and platelet aggregation studies 
should be performed as soon as the blood sampling is performed. 
Even though, they are conflicting these studies open news questions; if iNO is 
selective for the pulmonary circulation in regard to its vasodilatory activity, this 
may not be true for others actions such as changes in platelet function; here the 
effect may be mediated by stable compounds such as nitrosothiols formed in the 
pulmonary circulation during inhalation and act systemically. 
 Left ventricular dysfunction 
There are several reports of the negative effects of inhaled NO in patients with 
left ventricular dysfunction and elevated pulmonary vascular resistance.103–108 
Inhaled NO produces selective pulmonary vasodilatation. However, in patients 
with elevated left atrial pressure due to left ventricular dysfunction, a decrease in 
pulmonary vascular resistance (induced by iNO) will lead to an increase in 
pulmonary venous return and hence to an increase in left atrial and left 
ventricular filling pressures; this may not be tolerated by a failing left ventricle 
working on the flat portion of the Frank-Starling curve.108 This effect may lead to 
rapid left heart failure and pulmonary oedema, most marked if the right ventricular 
pressure is suprasystemic and the left cavity small.103 Such a phenomenon has 
been confirmed by Rosales et al. in a patient with a small non compliant left 
atrium and ventricle after repair of total anomalous pulmonary venous return.109 
Indeed several years ago, Wood already suggested that an elevation in 
pulmonary vascular resistance may protect the lungs from pulmonary oedema in 
severe mitral stenosis.110 A similar postulate may be applicable in patients with 
severe left ventricular dysfunction or poor left atrial and ventricular compliance. 
This pathophysiologic explanation has been confirmed, and a direct negative 
inotropic effect excluded by recent studies111,112 in pigs and in patients with 
normal left ventricular function.113 Loh et al.,114 in a canine model of 
cardiomyopathy, showed that iNO decreased pulmonary vascular resistance and 
increased left ventricular filling pressures, which was related to an increase in 
pulmonary venous return, without any effect on the contractile or relaxation 
properties of the left ventricular. This effect was further confirmed by Hayward et 
al. in patients with dilated cardiomyopathy,115 
Even though iNO does not seem to have direct negative inotropic effects, these 
factors highlight the need for careful observation and intensive monitoring during 
NO inhalation in patients with left ventricular failure, if left ventricular afterload is 
not lowered concomitantly. 
 
Inhaled nitric oxide applications 
 Neonates with hypoxaemic respiratory failure 
Inhaled NO was targeted early to the newborn with persistent pulmonary 
hypertension of the newborn (PPHN). The first application of iNO in the newborn 
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was described almost 10 years ago by Roberts et al. and Kinsella et al.116,117 
They used iNO in term neonates with hypoxaemic respiratory failure and found a 
rapid improvement in oxygenation without any lowering of the systemic pressure. 
Several studies have then confirmed its efficacy in this group of patients.59,118–120 
PPHN is a syndrome associated with diverse neonatal cardiopulmonary 
disorders, which are characterised by a high pulmonary vascular resistance with 
right to left shunt of deoxygenated blood across the ductus arteriosus and/or the 
foramen ovale. The role of echocardiography to confirm the diagnosis and 
conduct therapy is therefore essential. Echocardiography also excludes structural 
congenital heart disease, which would contraindicate the use of iNO. In neonates 
with hypoxaemic respiratory failure the success of iNO was mainly measured by 
the number of neonates in whom ECMO could be avoided.46,121 A multicentre, 
randomised study with 248 neonates > 34 weeks who required mechanical 
ventilation and had an OI of 25 or above, showed that fewer neonates required 
ECMO in the group treated with iNO. However, the mortality was similar in both 
groups.121 The most significant effect occurred in the newborns with PPHN. 
Patients with isolated PPHN generally show an immediate and dramatic 
response to iNO, whereas patients with parenchymal lung disease have less 
impressive responses. The latter requires specific and adapted mechanical 
ventilation to obtain adequate lung inflation and recruitment. This allows iNO to 
reach alveoli and diffuse to the smooth muscle cells. In the presence of 
atelectasis and mucous plugs, iNO can not reach the alveolocapillary membrane 
and thus may appear ineffective. This explains why iNO response is mainly 
disease related in this group of patients. 
Wessel and al speculated that the use of specific lung expansion with the use of 
NO lead to a reduced use of ECMO in neonates with PPHN. Kinsella et al. 
reported that high frequency oscillation with iNO was better than high frequency 
oscillation alone, or iNO with conventional ventilation.118 Again, among infants 
ventilated by high frequency oscillation, those receiving inhaled NO had a 
reduced need for ECMO, but no change in mortality in a prospective randomised 
study.122 In conclusion, pure hypoxia associated with PPHN but without additional 
parenchymal lung disease has a high rate of clinical response to iNO. 
Extensive supportive data demonstrate the overall safety and efficacy of iNO in 
hypoxaemic respiratory failure in term neonates, as evidenced by its recent 
approval by the United States Food and Drug administration. 
Neonates diagnosed with congenital diaphragmatic hernia represent a particular 
group of patients within the neonates with hypoxaemic respiratory failure. 
Although iNO may be effective in some patients, as a group, neonates with 
congenital diaphragmatic hernia, are poor responders.123 This may be due to 
several factors including pulmonary hypoplasia, left ventricular size and function 
as well as structural abnormalities of the pulmonary vascular bed. 
 NO application in premature neonates 
In preterm neonates, hypoxaemic respiratory failure is almost invariably 
associated with hyaline membrane disease and respiratory distress syndrome 
(RDS). Preliminary studies in premature neonates with severe hypoxaemic 
respiratory failure support the efficacy of iNO to improve arterial oxygenation. 
Peliowski et al. reported their experience with iNO therapy in 8 premature 
neonates between 24 and 31 weeks of gestation.124 Significant reduction of 
oxygen index and mean airway pressures were described during iNO inhalation. 
Skimming et al compared the effect of 5 ppm versus 20 ppm in 23 preterm 
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neonates with severe RDS.125 Both concentrations of iNO induced an 
improvement in oxygenation. 
Subhedar et al. included 42 preterm neonates < 32 weeks, who were recruited at 
4 days of age if they were at high risk of developing bronchopulmonary 
dysplasia.126 Neonates were randomised to receive either iNO or 
dexamethasone, or both or none of the treatments. There was no difference in 
survival, chronic lung disease, or intracranial haemorrhage between iNO treated 
infants and control group. One of the major restrictions of these studies is the 
small number of neonates randomised. Two recent double blind randomised 
studies have been published. Kinsella et al assessed the effects of low dose iNO 
(5ppm) in 80 premature neonates with severe hypoxaemic respiratory failure with 
survival to discharge as a primary endpoint.101 iNO induced a significant 
improvement in oxygenation after 60 minutes. There was, however, no difference 
in survival. The low dose of iNO did not increase the risk of bleeding 
complications. They further hypothesised that low dose iNO may be effective as a 
lung anti-inflammatory therapy because this treatment may affect neutrophil 
adhesion in the microcirculation. The Franco Belgium Collaborative NO trial 
group randomly assigned 204 preterm (<33 weeks) and near term neonates (≥ 33 
weeks) with oxygenation indices from 12.5 to 50 and 15 to 40, respectively, to 10 
ppm iNO (n=105) or control ventilation therapy without iNO (n=99).100 Neonates 
with a gestational age ≥ 33 weeks had a significant reduction in OI, duration of 
mechanical ventilation and duration of NICU stay. In the group < 33 weeks there 
were no significant differences. 
The use of iNO remains somewhat controversial in premature neonates. Low 
doses of iNO can be of benefit for premature neonates with severe hypoxaemic 
respiratory failure allowing improvement of oxygenation and decreasing the need 
for mechanical ventilation but so far no effect on mortality has been 
demonstrated. The possibility that iNO may have a preventive effect on chronic 
lung disease is a hypothesis that has not yet been studied. However, there are no 
data to support the use of iNO routinely in premature neonates and it should be 
used in the context of prospective trials. 
 Hypoxaemic respiratory failure in infants and children 
Acute respiratory distress syndrome (ARDS) is an acute form of severe alveolar-
capillary injury that evolves after a direct or indirect lung insult. It begins as 
noncardiogenic pulmonary edema and develops into a neutrophilic alveolitis, and, 
later, pulmonary fibrosis.127 
Patients with adult respiratory distress syndrome and hypoxaemic respiratory 
failure may also benefit from iNO.42,80,128,129 Pulmonary hypertension and 
hypoxaemia secondary to a ventilation/perfusion mismatch, or a right to left shunt 
through a foramen ovale or both are prominent features of the disease. However, 
despite improved oxygenation iNO did not change mortality in large groups of 
patients.130,131 
Dobyns et al included 108 childrens with a median age of 2.5 years in a 
prospective, multicenter study.132 The children were randomised between a 
placebo group (n=55) and a control group (n=53) with 10 ppm of iNO for 3 to 7 
days. A statistically significant improvement in both OI and PaO2/FiO2 was found 
in the iNO group at both 4 and 12 hours of treatment, but as in adults, no change 
in mortality was obtained. 
From the data provided available so far, iNO had no effect on mortality and only 
transiently improved oxygenation in ARDS in children and/or adults.132–135 
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In conclusion iNO, may be useful as a rescue treatment for a short period of time 
in patients with ARDS. The transient improvement in oxygenation following 
administration of iNO may be explained by a reduced ventilation/perfusion 
mismatching. In the long run however, pulmonary damage secondary to volume 
and barotraumatism, oxygen toxicity, and cytokines, may over-ride any potential 
benefit of iNO. 
Inhaled nitric oxide and cardiac disease 
 Assessment of pulmonary vascular reactivity 
The assessment of pulmonary vascular reactivity plays an important role in the 
management of chronic pulmonary hypertension. In children with heart disease 
and significantly increased pulmonary blood flow or pulmonary venous 
hypertension, progressive pulmonary vessel wall damage can lead to medial and 
intimal changes, smooth muscle cell hypertrophy and hyperplasia and finally 
fibrosis and obliteration.136,137 The increase in muscularity induces some degree 
of vasoconstriction. Therefore, elevated pulmonary vascular resistance, 
encountered at all stages of increased muscularity, may in part be due to this 
reversible vasoconstriction. Different diagnostic techniques are offered to 
evaluate the degree and progression of pulmonary vascular disease. 
Morphologic criteria based on lung biopsies have been first described by Heath 
and Edwards.138 They described six grades of progressive structural changes in 
the small pulmonary arteries of patients with congenital heart disease. 
Rabinovitch, then described a morphometric method which evaluated the 
extension of muscle into usually non muscularised peripheral arteries.139 Despite 
reports showing a good correlation of biopsy with postoperative 
haemodynamics,140 the predictive value of lung biopsies remains controversial as 
lesions may be unequally distributed within the lungs; thus the degree of lesions 
may be misinterpreted. Moreover, this static description does not take into 
account the dynamics of the pulmonary vascular bed. In addition, open lung 
biopsy is required, as transbronchial route does not offer adequate material, and 
this it is not without risk.141,142 
Standard catheterization and assessment of pulmonary vascular reactivity 
remains however, the test performed in most cardiac centers to assess 
operability, even though there are some limitations, such as difficulties in 
measurement of cardiac output and failure to take into consideration the pulsatile 
nature of the pulmonary circulation. 
New techniques using intravascular ultrasound and assessing the pulsatility and 
distensibility of the pulmonary arteries are being studied, and may offer new 
insights in the assessment of pulmonary vascular disease in the future.143–145 
Since the early 60's, when high percentage inspired oxygen was recognised as a 
pulmonary vasodilator in congenital heart disease,7,8 100% oxygen (O2) has been 
used to assess pulmonary vascular reactivity routinely. Conclusions based on 
this unique test however were not considered as sufficient.146 Other agents such 
as tolazoline,147 prostacyclin,11 or calcium channel blockers,148 have been used 
but they all share the same problem.149 As they require intravenous 
administration, their results may be confounded by changes in systemic 
hemodynamics and intrapulmonary shunts. The use of a selective pulmonary 
vasodilator such as iNO offers the clinician important advantages in the 
investigation of pulmonary vascular reactivity. Several studies have been 
performed to assess the effect of iNO on pulmonary vascular resistance in 
congenital heart disease. First, Roberts et al studied the effect of 20 and 80 ppm 
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inhaled nitric oxide in 10 patients with congenital heart disease.39 The maximum 
reduction in pulmonary vascular resistance was obtained with the highest dose. 
There was an additive effect when a high dose of inspired oxygen was delivered 
simultaneously. Winberg et al showed, in addition, that children with a normal 
pulmonary vascular tone did not respond to nitric oxide.150 Day et al failed to 
demonstrate an increased response to 60 ppm as compared to 12 ppm.151 Berner 
et al studied the effect of 35 ppm nitric oxide in children with long-standing 
pulmonary hypertension and congenital heart disease.37 They showed that the 
decline of the selective response to nitric oxide seems to parallel the progression 
of established vascular disease and thus may be helpful for the selection of 
patients for corrective surgery. Atz et al studied the effects of nitric oxide and high 
levels of inspired oxygen. Inhalation of 80 ppm nitric oxide and 100% oxygen 
produced a similar degree of pulmonary vasodilation.152 In addition the 
combination of both vasodilators provides additional pulmonary vasodilation and 
may identify patients who would not respond to each substance alone. 
Rimensberger et al compared the effects of 20 ppm nitric oxide and aerosolised 
iloprost (25ng/Kg/min).153 They concluded that in children with pulmonary 
hypertension and congenital heart disease both inhaled nitric oxide and 
aerosolised iloprost are equally effective in selectively lowering pulmonary 
vascular resistance. The combination, however, failed to prove more potent than 
either substance alone. 
 End-stage cardiac failure and cardiopulmonary transplantation 
Severe pulmonary vascular changes have been found in patients with right 
ventricular failure after heart transplant.154,155 Therefore, the preoperative 
assessment of the degree of vasoconstriction versus fixed obliterative disease is 
crucial in the decision to transplant the heart alone or to proceed with heart and 
lung transplantation.156 There are several reports of the effects of iNO in patients 
with elevated pulmonary vascular resistance before transplantation.103,104 NO 
produces selective pulmonary vasodilation without systemic hypotension, which 
is a common limiting feature of intravenous prostacyclin and sodium 
nitroprusside.156,157 Inhaled NO provides an effective assessment of pulmonary 
vascular resistance before cardiac transplantation. 
 Post-operative differentiation between anatomic obstruction and 
vasospasm 
Pulmonary hypertension after surgery for congenital heart disease may pose 
diagnostic and therapeutic management dilemmas and complicate considerably 
the early post-operative course.47,82,147,158 Pulmonary hypertension may be 
episodic or sustained in the immediate postoperative period with resolution once 
recovery from cardiopulmonary bypass is complete. Certain patients, particularly 
neonates with obstructed anomalous pulmonary venous drainage, truncus 
arteriosus and hypoplastic left heart syndrome, have marked pulmonary vascular 
lability postoperatively. Even with invasive monitoring it may be difficult to 
differentiate pulmonary vascular lability from residual obstruction at the surgical 
anastomosis. Indeed, the measurement of elevated pulmonary artery pressures 
from a proximally inserted catheter or the noninvasive recognition of an elevated 
right ventricular pressure by Doppler interrogation may represent either distal 
pulmonary artery obstruction (amenable to treatment by surgical or interventional 
catheterisation techniques) or pulmonary vasospasm. It is especially important to 
resolve vasospasm from fixed obstruction to pulmonary blood flow when the 
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temporary support of the children of the circulation with ECMO is 
considered.159,160 
Two studies showed that a trial of inhaled nitric oxide may differentiate anatomic 
obstruction from pulmonary vasoconstriction.161,162 Both demonstrated that failure 
to respond to inhaled nitric oxide in neonates after cardiac surgery should prompt 
investigations looking for lesions amenable to surgical correction. A trial of 
inhaled nitric oxide after cardiac surgery may be useful to differentiate reversible 
pulmonary vasoconstriction from fixed anatomic obstruction and may provide 
information if temporary support with extracorporeal membrane oxygenation is 
considered. 
 Management of pulmonary hypertension after cardiac surgery 
Sudden pulmonary hypertensive crises may punctuate the post-operative course 
despite accurate surgery and are associated with significant mortality and 
morbidity.158 For many years strategies aimed at minimising increases in 
pulmonary vascular resistance following repair of congenital heart disease have 
included hyperventilation to induce a respiratory alkalosis9,163 and the use of 
sedation and paralysis.164 Also, various vasodilator drugs such as tolazoline, 
prostacyclin, phenoxybenzamine and nitrodilators12,13,147,165,166 have been used to 
reduce pulmonary arterial pressure. However, their lack of selectivity renders 
their use particularly risky in congenital heart disease patients. There is particular 
appeal in the therapeutic opportunities afforded by iNO in this setting. 
Right ventricular function may be compromised following congenital heart 
disease repair because of cardiopulmonary bypass and direct injury by the 
surgical procedure itself. Increased pulmonary vascular resistance further 
compromises right ventricular function, and dilate the right ventricle inducing an 
intrapericardial tamponnade of the left ventricle.167 This secondary diastolic 
dysfunction further reduces cardiac output leading to aortic hypotension and 
coronary hypoperfusion of the right ventricle leading to a vicious circle.168 Inhaled 
NO improves right ventricular systolic function by decreasing afterload and 
reduces the left ventricular tamponnade thus restoring aortic pressure and 
coronary perfusion.169–171 It has been applied in several different congenital heart 
disease, other than left to right shunts, where an increased PVR may complicate 
post operative course such as mitral valve stenosis,172 bicavopulmonary 
anastomosis,173,174 the Fontan circulation175,176 or post cardiac and/or lung 
transplant.63,177–180 Several reports confirm that iNO corrects right ventricular 
dysfunction after left ventricular assist device implantation181 perhaps through an 
increase in pulmonary venous return and left atrial pressure, and facilitating pump 
flow.182 
Wessel et al. showed that pulmonary endothelial dysfunction was present after 
cardiopulmonary bypass: thus the response to acetylcholine was attenuated but 
the response to inhaled nitric oxide was maintained.16 They hypothesized that a 
dysfunctional endothelium with reduced endogenous nitric oxide release may 
contribute to post operative pulmonary hypertension. Journois et al demonstrated 
that inhaled nitric oxide was a useful therapy for pulmonary hypertensive crisis 
refractory to conventional treatment.183 Miller et al. demonstrated that low doses 
of nitric oxide (2 ppm) appear to be effective in similar patients.47 Beghetti et al. 
demonstrated that the effect of low dose nitric oxide was maintained over several 
days at concentrations carrying little risks of toxicity.82 Nitric oxide has been used 
with success in several different congenital heart defects where increased 
pulmonary vascular resistance may complicate post operative course such as 
mitral valve stenosis,172 total anomalous pulmonary venous return,79 bidirectional 
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Glenn anastomosis,173 the Fontan circulation176 or post heart and/or lung 
transplant.63 A beneficial effect in patients with cavopulmonary anastomosis is not 
consistently reported and this despite of an increase in cGMP levels which is 
proof of effective deliver.184 
Two recent studies reported the prophylactic use of iNO after cardiac surgery. 
They showed controversial results. Miller et al showed that in infants at high risk 
of pulmonary hypertension, routine use of inhaled nitric oxide after congenital 
heart surgery can lessen the risk of pulmonary hypertensive crises and shorten 
the postoperative course, with no toxic effects,185 whereas Day et al showed no 
benefit.186 
 Other potential applications 
After lung transplantation, acute but transient graft dysfunction (manifested by 
pulmonary hypertension with hypoxaemia) challenges and escalates the post-
operative management.63,180 Inhaled NO is effective in reducing pulmonary 
vascular resistance and intrapulmonary shunt after lung transplantation. It was 
indeed more effective than acetylcholine, suggesting that ischemic preservation 
of the donor lung may result in endothelial dysfunction and contribute to 
pulmonary hypertension.63 
Some reports demonstrated the efficacy of iNO to increase PaO2 and decrease 
pulmonary vascular resistance in patients with chronic obstructive airway 
disease.187–189 The bronchodilatory effect of iNO in obstructive airway disease 
remains a matter of debate. Human observations190 do not suggest a marked 
bronchodilator role for NO compared to guinea pigs studies.191 Inhaled NO may 
also be useful in severe asthma.192 Some studies have shown that endogenous 
NO production appears to be increased in asthmatics secondary to the 
stimulation of inducible NO synthase by mediators of inflammation.193–196 
The number of pathologies in which iNO has been tested with success is 
continuously growing (primary pulmonary hypertension,157,197–201 pulmonary 
embolism,202 and sickle cell disease.203–205 
 
Conclusion 
Inhalation of nitric oxide has made the journey from the bench to the bedside 
more rapidly than any other drug. Inhaled NO is a selective vasodilator for the 
constricted pulmonary vascular bed and improves ventilation perfusion matching 
in respiratory failure. In paediatrics, the use of iNO in term neonates with 
hypoxaemic respiratory failure, in the assessment of pulmonary vascular 
reactivity and in the treatment of postoperative pulmonary hypertension in 
congenital heart disease is well recognised and accepted. Several other 
applications have been described but caution must be the rule with a drug that 
shows potential adverse and toxic effects. Still, randomised double blind trials are 
required to define its effects in premature neonates and even after cardiac 
surgery, to define its effects on morbidity and mortality. Several questions are still 
unanswered regarding its safety in regards to long-term administration. 
Meanwhile, this unique molecule continues to provide us with insight into the 
mechanisms of pulmonary vascular disease. In addition, new roles in 
inflammation may include the modification of the platelet and /or leukocytes 
function and its effects in the development of chronic lung disease. 
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